The total return over the past 12 months is -49.04% vs. +16.94% for the S&P 500. So far it's up -7.49% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (49.04%) | (28.79%) | N/A | N/A | N/A | N/A |
| Total Return CAGR | (49.04%) | (28.79%) | N/A | N/A | N/A | N/A |
| Revenue CAGR | (17.90%) | N/A | (2.32%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Prime Medicine, Inc. (PRME)
| Year | Start price | End price | PRME Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.47 | $3.21 | (7.49%) | +14.51% | (22.00%) |
| 2025 | $2.92 | $3.47 | +18.84% | +17.72% | +1.12% |
| 2024 | $8.86 | $2.92 | (67.04%) | +24.89% | (91.93%) |
| 2023 | $18.58 | $8.86 | (52.31%) | +26.19% | (78.50%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
